 "Bharat Biotech applies for emergency use authorisation for Covaxin")
After Pfizer and Serum Institute of India, Hyderabad-based Bharat Biotech has applied for an emergency use authorisation for its investigational vaccine candidate, Covaxin, to the Indian regulator. The firm is conducting its Phase 3 trial, involving 26,000 participants.
This is one of the largest efficacy trials held in the country. The firm has Phase 1 and Phase 2 data ready and will submit the interim data from the large-scale efficacy trials to the Drug Controller General of India.
Officials from the Central Drugs Standard Control Organization and the Indian Council of Medical Research have been in touch with the firm.
One subscription. Two world-class reads.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%